Madhav Rajan - IShares Medical Independent Trustee
| IHI Etf | USD 60.69 0.04 0.07% |
Mr. Madhav V. Rajan serves as an Independent Trustee of Ishares Dow Jones US Medical Devices Index Fund since May 16, 2011. Mr. Rajan has served as a Director of iShares, Inc. and a Director of iShares MSCI Russia Capped Index Fund, Inc. since 2011. Mr. Rajan is the Gregor G. Peterson Professor of Accounting at the Stanford Graduate School of Business. He has taught accounting for over 20 years to undergraduate, MBA and law students, as well as to senior executives. Mr. Rajan serves as the Senior Associate Dean for Academic Affairs and head of the MBA Program at the Stanford Graduate School of Business. Mr. Rajan served as editor of The Accounting Review from 2002 to 2008 and is coauthor of Cost Accounting A Managerial Emphasis, a cost accounting textbook
| Age | 52 |
| Tenure | 13 years |
| Professional Marks | MBA |
| Issuer | iShares |
| Inception Date | 2006-05-01 |
| Benchmark | Dow Jones U.S. Select Medical Equipment Index |
| Entity Type | Regulated Investment Company |
| Asset Under Management | 4.92 Billion |
| Average Trading Valume | 478,081.5 |
| Asset Type | Equity |
| Category | Sector |
| Focus | Health Care |
| Market Concentration | Developed Markets |
Similar Fund Executives
| Showing other executives | One Year Return | ||
| Robert Kapito | iShares Expanded Tech Software | 62 | |
| Robert Silver | iShares Healthcare ETF | 57 | |
| Cecilia Herbert | iShares Healthcare ETF | 67 | |
| Charles Hurty | iShares Healthcare ETF | 72 | |
| Charles Hurty | iShares Pharmaceuticals ETF | 72 | |
| John Kerrigan | iShares Healthcare ETF | 60 | |
| Eilleen Clavere | iShares Expanded Tech Software | 60 | |
| John Martinez | iShares Pharmaceuticals ETF | 55 | |
| John Martinez | iShares Aerospace Defense | 55 | |
| John Kerrigan | iShares Aerospace Defense | 60 | |
| Eilleen Clavere | iShares Aerospace Defense | 60 | |
| Cecilia Herbert | iShares Aerospace Defense | 67 | |
| John Kerrigan | iShares Expanded Tech Software | 60 | |
| Darrell Duffie | iShares Aerospace Defense | 61 | |
| Eilleen Clavere | iShares Healthcare ETF | 60 | |
| Robert Silver | iShares Aerospace Defense | 57 | |
| Eilleen Clavere | iShares Pharmaceuticals ETF | 60 | |
| John Kerrigan | iShares Pharmaceuticals ETF | 60 | |
| Robert Kapito | iShares Pharmaceuticals ETF | 62 | |
| Robert Silver | iShares Pharmaceuticals ETF | 57 | |
| John Martinez | iShares Expanded Tech Software | 55 | |
iShares Medical Devices Money Managers
| Geoffrey Flynn, Chief Operating Officer, Executive Vice President | ||
| Robert Silver, Independent Trustee | ||
| John Kerrigan, Independent Trustee | ||
| Madhav Rajan, Independent Trustee | ||
| Matt Tucker, Vice President | ||
| Cecilia Herbert, Independent Trustee | ||
| Michael Latham, President Trustee | ||
| Jack Gee, Chief Financial Officer, Treasurer | ||
| Charles Hurty, Independent Trustee | ||
| Eilleen Clavere, Secretary | ||
| George Parker, Independent Chairman of the Board of Trustees | ||
| John Martinez, Independent Trustee | ||
| Amy Schioldager, Executive Vice President | ||
| Robert Kapito, Trustee | ||
| Ira Shapiro, Vice President Chief Legal Officer |
IShares Etf Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right etf is not an easy task. Is IShares Medical a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Price To Earning | 24.14 X | |||
| Price To Book | 3.03 X | |||
| Price To Sales | 3.38 X | |||
| Number Of Employees | 15 | |||
| Beta | 1.04 | |||
| Total Asset | 5.79 B | |||
| One Year Return | 21.30 % | |||
| Three Year Return | (1.40) % | |||
| Five Year Return | 7.70 % | |||
| Ten Year Return | 13.10 % |
Currently Active Assets on Macroaxis
When determining whether iShares Medical Devices offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of IShares Medical's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Ishares Medical Devices Etf. Outlined below are crucial reports that will aid in making a well-informed decision on Ishares Medical Devices Etf:Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in iShares Medical Devices. Also, note that the market value of any etf could be closely tied with the direction of predictive economic indicators such as signals in rate. You can also try the Global Correlations module to find global opportunities by holding instruments from different markets.
The market value of iShares Medical Devices is measured differently than its book value, which is the value of IShares that is recorded on the company's balance sheet. Investors also form their own opinion of IShares Medical's value that differs from its market value or its book value, called intrinsic value, which is IShares Medical's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because IShares Medical's market value can be influenced by many factors that don't directly affect IShares Medical's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between IShares Medical's value and its price as these two are different measures arrived at by different means. Investors typically determine if IShares Medical is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, IShares Medical's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.